ischemic cardiomyopathy


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia.

ischemic cardiomyopathy

Cardiology A disorder caused by myocardial hypoxia, which compromises the heart's ability to efficiently pump blood; IC may cause heart failure and is a complication of cardiac ischemia, especially affecting older ♂, a disparity that ↓ with advancing geezhood Risks factors Personal or family Hx of MI, angina, unstable angina, ASHD, or other CAD; HTN, smoking, DM, high fat diet, ↑ cholesterol, obesity, stress can all precipitate IC Management rGH improves hemodynamics, clinical function. See Growth hormone.
References in periodicals archive ?
Yu CM, Fung WH, Lin H, Zhang Q, Sanderson JE, Lau CP Predictors of left ventricular reverse remodeling after cardiac resynchronization therapy for heart failure secondary to idiopathic dilated or ischemic cardiomyopathy.
The answer depends on two further questions: Should ischemic cardiomyopathy be managed differently from cardiomyopathy with a nonischemic etiology?
The device was implanted in a 78-year-old man with a history of ischemic cardiomyopathy due to coronary artery disease who underwent CABG in 1999 and replacement of the aortic valve in 2002, by cardiologist Dr.
The study involved 391 patients with chronic heart failure due to ischemic cardiomyopathy.
Dib today at the ACC press briefing entitled "Late-Breaking Clinical Trials: Mechanisms and New Therapeutics Approaches" and subsequently detailed in his presentation, "Three Year Follow-up of Autologous Myoblast Transplantation for Ischemic Cardiomyopathy in Patients Undergoing Coronary Artery Bypass Grafting.
The study enrolled 768 consecutive patients with ischemic cardiomyopathy and an ejection fraction less than or equal to 35%.
PliCath HF is a catheter-based device intended to resize the left ventricle in heart failure patients with ischemic cardiomyopathy.
MADIT II was a very well-done study, but it does not mean that all patients with ischemic cardiomyopathy and an ejection fraction less than 30% should receive an ICD.
The Myoblast Autologous Graft in Ischemic Cardiomyopathy (MAGIC) trial was designed to test whether autologous skeletal myoblasts can be used to reverse damage done to cardiac muscle following a heart attack, or to safely halt a patient's further progression of heart failure.
Six patients had ischemic cardiomyopathy while one had idiopathic cardiomyopathy.
In the two-phase, multi-center trial, 240 patients suffering from ischemic cardiomyopathy at 35 sites in eleven countries will be treated with C-Cure.